Xin Lang Cai Jing·2026-02-25 07:38Core Viewpoint - The article discusses the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., highlighting its growth in overseas revenue and the impact of currency depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink, established in 1998, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company's main business segments include formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. Financial Performance - For the period from January to September 2025, Hepalink achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company reported that 93.04% of its revenue comes from overseas, benefiting from the depreciation of the Chinese yuan [3]. Market Activity - On February 25, Hepalink's stock rose by 0.74%, with a trading volume of 39.7381 million yuan and a turnover rate of 0.26%, leading to a total market capitalization of 17.945 billion yuan [1]. - The stock has seen a net outflow of 1.7001 million yuan from major investors, indicating a reduction in holdings over the past three days [4][5]. Technical Analysis - The average trading cost of Hepalink's shares is 11.67 yuan, with the stock currently near a support level of 12.23 yuan, suggesting potential for a rebound if this level holds [6].